Amphastar Pharmaceuticals, Inc. business relationships
Companies named in Amphastar Pharmaceuticals, Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Amphastar Pharmaceuticals, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- - / 10
- AI naming
- - / 100
- Agent readiness
- - / 100
- AI adoption
- - / 100
Layers: Peptides
Named in Amphastar Pharmaceuticals, Inc.’s annual report 4
“Total BAQSIMI ® sales growth, including units sold by Lilly in 2024 which were accounted for in other revenues, was 12%.” SEC filing
“...le and accrued liabilities increased primarily due to the increase in accrued customer fees and rebates associated with BAQSIMI ® sales, as we continued to assume distribution responsibilities for BAQSIMI ® from Lilly to our customers in the United States and certain other countries throughout 2024.” SEC filing
“The increase in selling, distribution and marketing expenses was primarily due to expenses related to the expansion of our sales and marketing efforts related to BAQSIMI ® , including expenses related to our co-promotion contract with MannKind, and sales efforts related to Primatene MIST ® .” SEC filing
“We have amended our supply agreement with MannKind, or the Supply Agreement and our option purchase agreement with MannKind, or the Option Agreement, multiple times to modify and extend the annual minimum purchase commitments under the Supply Agreement and the Option Agreement.” SEC filing
Companies whose annual reports name Amphastar Pharmaceuticals, Inc. 1
“Cost of goods sold excludes the cost of insulin purchased under the Company's Insulin Supply Agreement (the "Insulin Supply Agreement") with Amphastar Pharmaceuticals, Inc. ("Amphastar").” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.